Hepatitis Monthly

Published by: Kowsar

Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis

Wenli Sai 1 , Li Wang 2 , Wenjie Zheng 1 , Junling Yang 1 , Liuhong Pan 3 , Yin Cai 4 , Liwei Qiu 1 , Haijian Zhang 1 , Wei Wu 1 and Dengfu Yao 1 , *
Authors Information
1 Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China
2 Medical School, Nantong University, Nantong, China
3 Department of Oncology, Affiliated Hospital of Nantong University, Nantong, China
4 Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China
Article information
  • Hepatitis Monthly: December 01, 2015, 15 (12); e32918
  • Published Online: December 29, 2015
  • Article Type: Research Article
  • Received: September 4, 2015
  • Revised: October 22, 2015
  • Accepted: November 21, 2015
  • DOI: 10.5812/hepatmon.32918

To Cite: Sai W, Wang L, Zheng W, Yang J, Pan L, et al. Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis, Hepat Mon. 2015 ; 15(12):e32918. doi: 10.5812/hepatmon.32918.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379(9822): 1245-55[DOI]
  • 2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646-74[DOI][PubMed]
  • 3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365(12): 1118-27[DOI][PubMed]
  • 4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6): 1264-1273 e1[DOI][PubMed]
  • 5. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5): 844-55[DOI][PubMed]
  • 6. Yao M, Yao DF, Bian YZ, Zhang CG, Qiu LW, Wu W, et al. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2011; 10(3): 289-94[PubMed]
  • 7. Wu CS, Lee TY, Chou RH, Yen CJ, Huang WC, Wu CY, et al. Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2014; 9(6)[DOI][PubMed]
  • 8. Yao D, Jiang D, Huang Z, Lu J, Tao Q, Yu Z, et al. Abnormal expression of hepatoma specific γ‐glutamyl transferase and alteration of γ‐glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer. 2000; 88(4): 761-9[DOI]
  • 9. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012; 44(6): 694-8[DOI][PubMed]
  • 10. Ma L, Ji L, Yu Y, Wang J. Novel molecular targets for diagnosis and treatment of hepatocellular carcinoma. Discov Med. 2015; 19(102): 7-14[PubMed]
  • 11. Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, et al. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013; 12(2): 171-9[PubMed]
  • 12. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015; 62(4): 956-67[DOI][PubMed]
  • 13. Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Graff A, Gusmirovic I, Solomon H, et al. Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 2004; 99(6): 1087-95[DOI][PubMed]
  • 14. Li QW, Chen HB, Li ZY, Shen P, Qu LL, Gong LL, et al. Preparation and characterization of anti-GP73 monoclonal antibodies and development of double-antibody sandwich ELISA. Asian Pac J Cancer Prev. 2015; 16(5): 2043-9[PubMed]
  • 15. Wang F, Long Q, Gong Y, Hu L, Zhang H, Oettgen P, et al. Epithelium-Specific ETS (ESE)-1 upregulated GP73 expression in hepatocellular carcinoma cells. Cell Biosci. 2014; 4(1): 76[DOI][PubMed]
  • 16. Wang Y, Yang H, Xu H, Lu X, Sang X, Zhong S, et al. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to alpha-Fetoprotein for hepatocellular carcinoma diagnosis. J Gastroenterol Hepatol. 2014; 29(3): 597-602[DOI][PubMed]
  • 17. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A. 2005; 102(3): 779-84[DOI][PubMed]
  • 18. Norton PA, Comunale MA, Krakover J, Rodemich L, Pirog N, D'Amelio A, et al. N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem. 2008; 104(1): 136-49[DOI][PubMed]
  • 19. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002; 35(6): 1431-40[DOI][PubMed]
  • 20. Yang J, Li J, Dai W, Wang F, Shen M, Chen K, et al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis. Exp Ther Med. 2015; 9(4): 1413-20[DOI][PubMed]
  • 21. Diagnostic criteria of primary hepatocellular carcinoma. Zhonghua Ganzangbing Zazhi. 2001;
  • 22. Qiao Y, Chen J, Li X, Wei H, Xiao F, Chang L, et al. Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin Biochem. 2014; 47(16-17): 216-22[DOI][PubMed]
  • 23. Liu Y, Zou Z, Zhu B, Hu Z, Zeng P. CXCL10 decreases GP73 expression in hepatoma cells at the early stage of hepatitis C virus (HCV) infection. Int J Mol Sci. 2013; 14(12): 24230-41[DOI][PubMed]
  • 24. Wei H, Zhang J, Li H, Ren H, Hao X, Huang Y. GP73, a new marker for diagnosing HBV-ACLF in population with chronic HBV infections. Diagn Microbiol Infect Dis. 2014; 79(1): 19-24[DOI][PubMed]
  • 25. Broker ME, Ijzermans JN, Witjes CD, van Vuuren HJ, de Man RA. The predictive value of Golgi protein 73 in differentiating benign from malignant liver tumors. PLoS One. 2014; 9(7)[DOI][PubMed]
  • 26. Shan SG, Gao YT, Xu YJ, Huang Y, Zhang Q, Zhai DK, et al. Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients. Hepatol Res. 2013; 43(11): 1199-210[DOI][PubMed]
  • 27. Sun Y, Yang H, Mao Y, Xu H, Zhang J, Li G, et al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol. 2011; 26(7): 1207-12[DOI][PubMed]
  • 28. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2009; 18(6): 1914-21[DOI][PubMed]
  • 29. Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013; 14(12): 23559-80[DOI][PubMed]
  • 30. Wang L, Yao M, Dong Z, Zhang Y, Yao D. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol. 2014; 35(1): 9-20[DOI][PubMed]
  • 31. Wang L, Yao M, Pan L, Qian Q, Yao D. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015; 14(4): 361-6[DOI]
  • 32. Li S, Yao D, Wang L, Wu W, Qiu L, Yao M, et al. Expression characteristics of hypoxia-inducible factor-1alpha and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat Mon. 2011; 11(10): 821-8[DOI][PubMed]
  • 33. Wang NY, Wang C, Li W, Wang GJ, Cui GZ, He H, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev. 2014; 15(4): 1539-44[PubMed]
  • 34. Xu WJ, Guo BL, Han YG, Shi L, Ma WS. Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels. Tumour Biol. 2014; 35(12): 12069-74[DOI][PubMed]
  • 35. Bao YX, Cao Q, Yang Y, Mao R, Xiao L, Zhang H, et al. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol. 2013; 8: 197[DOI][PubMed]
  • 36. Tian L, Wang Y, Xu D, Gui J, Jia X, Tong H, et al. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer. 2011; 129(8): 1923-31[DOI][PubMed]
  • 37. Ozkan H, Erdal H, Tutkak H, Karaeren Z, Yakut M, Yuksel O, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion. 2011; 83(1-2): 83-8[DOI][PubMed]
  • 38. Witjes CD, van Aalten SM, Steyerberg EW, Borsboom GJ, de Man RA, Verhoef C, et al. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 2013; 7(1): 59-64[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments